Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | TSHR | P16473 | 5/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21495096 | 0.84 | TP53 (0.47) | TDP1TP53ALDH1A1TSHRHSD17B10 | |
| SCHEMBL1961187 | 0.84 | TP53 (0.47) | TDP1TP53ALDH1A1TSHRHSD17B10 | |
| SCHEMBL6472594 | 0.82 | PSEN1 (0.35) | ALDH1A1 | |
| SCHEMBL26664767 | 0.82 | TDP1 (0.35) | TDP1HSD17B10ERN1 | |
| SCHEMBL6443959 | 0.82 | TDP1 (0.35) | TDP1HSD17B10ERN1 | |
| SCHEMBL9901514 | 0.81 | ALKBH3 (0.35) | ALDH1A1MAPTLMNAMEN1POLB | |
| SCHEMBL6446720 | 0.81 | CYP3A4 (0.39) | TDP1TP53ALDH1A1TSHRCYP3A4 | |
| SCHEMBL20551400 | 0.77 | MDM2 (0.38) | TDP1TP53CYP3A4LMNAHTT | |
| SCHEMBL8805467 | 0.77 | TSHR (0.43) | TDP1TP53ALDH1A1TSHRHSD17B10 | |
| SCHEMBL20551547 | 0.77 | HTT (0.42) | TDP1ALDH1A1HTTERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3619209-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018203298-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-08 | — | — | WO | disclosed |
| EP-3080127-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086499-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| EP-2758380-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013041468-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013003298-A2 | INHIBITORS OF PDE10 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-03 | — | — | WO | disclosed |
| EP-2348860-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010051549-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-2155740-A1 | HETARYLANILINES AS MODULATORS FOR AMYLOID BETA | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| EP-2056817-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | Bayer HealthCare AG (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008138753-A1 | HETARYLANILINES AS MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008025509-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
| EP-1583742-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004060870-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |